home / stock / vivo / vivo news


VIVO News and Press, Meridian Bioscience Inc. From 09/22/22

Stock Information

Company Name: Meridian Bioscience Inc.
Stock Symbol: VIVO
Market: NASDAQ
Website: meridianbioscience.com

Menu

VIVO VIVO Quote VIVO Short VIVO News VIVO Articles VIVO Message Board
Get VIVO Alerts

News, Short Squeeze, Breakout and More Instantly...

VIVO - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AERI, CYBE, GMTX, VIVO

NEW YORK, NY / ACCESSWIRE / September 22, 2022 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Aerie Pharmaceuticals, Inc. (NA...

VIVO - Meridian Bioscience Non-GAAP EPS of $0.16 misses by $0.01, revenue of $67.8M beats by $1M

Meridian Bioscience press release ( NASDAQ: VIVO ): Q3 Non-GAAP EPS of $0.16 misses by $0.01 . Revenue of $67.8M (+6.8% Y/Y) beats by $1M . Due to the pending transaction, Meridian will no longer hold conference calls to discuss its quarterly financial results ...

VIVO - MERIDIAN BIOSCIENCE REPORTS THIRD QUARTER FISCAL 2022 OPERATING RESULTS

MERIDIAN BIOSCIENCE REPORTS THIRD QUARTER FISCAL 2022 OPERATING RESULTS PR Newswire CINCINNATI , Aug. 5, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the third quarter ended June 30, 2022 . ...

VIVO - FDA re-authorizes emergency use approval for Meridian's Revogene COVID-19 test

Meridian Bioscience ( NASDAQ: VIVO ) on Friday said the U.S. FDA had re-authorized its emergency use approval for the company's Revogene COVID-19 molecular diagnostic test. VIVO had initially received the emergency use nod in early Nov. last year. However, it was d...

VIVO - Meridian Bioscience Receives Re-Authorization from FDA for its Revogene® SARS-CoV-2 Molecular Assay

Meridian Bioscience Receives Re-Authorization from FDA for its Revogene® SARS-CoV-2 Molecular Assay PR Newswire CINCINNATI , July 29, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solut...

VIVO - SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates RFP, VIVO, SMED, ONEM

NEW YORK, NY / ACCESSWIRE / July 28, 2022 / Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Resolute Forest Products Inc. (NYSE:...

VIVO - Meridian Bioscience: High-Probability Merger Arbitrage

This is a mid-cap going private transaction offering a 9% annualized return. US diagnostic test kit maker Meridian Bioscience is being taken private by a South Korean buyer consortium. I expect the transaction to close given strong strategic rationale while shareholder and regulat...

VIVO - INVESTIGATION NOTICE: Halper Sadeh LLP Investigates HMTV, VIVO, LJPC, EURN

NEW YORK, NY / ACCESSWIRE / July 13, 2022 / Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Hemisphere Media Group, Inc. (NASDAQ...

VIVO - INVESTIGATION NOTICE: Halper Sadeh LLP Investigates ZEN, VIVO, SIMO, RADA

NEW YORK, NY / ACCESSWIRE / July 12, 2022 / Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Zendesk, Inc. (NYSE:ZEN)'s sale to...

VIVO - INVESTIGATION NOTICE: Halper Sadeh LLP Investigates RFP, VIVO, FSI

NEW YORK, NY / ACCESSWIRE / July 11, 2022 / Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Resolute Forest Products Inc. (NYSE:...

Previous 10 Next 10